MiR-142-3p functions as a tumor suppressor by targeting RAC1/PAK1 pathway in breast cancer |
| |
| Authors: | Tao Xu Bang-Shun He Bei Pan Yu-Qin Pan Hui-Ling Sun Xiang-Xiang Liu Xue-Ni Xu Xiao-Xiang Chen Kai-Xuan Zeng Mu Xu Shu-Kui Wang |
| |
| Affiliation: | 1. General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China;2. General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China Medical College, Southeast University, Nanjing, China |
| |
| Abstract: | MicroRNA-142-3p (miR-142-3p) was previously investigated in various cancers, whereas, it's role in breast cancer (BC) remains far from understood. In this study, we found that miR-142-3p was markedly decreased both in cell lines and BC tumor tissues. Elevated miR-142-3p expression suppressed growth and metastasis of BC cell lines via gain-of-function assay in vitro and in vivo. Mechanistically, miR-142-3p could regulate the ras-related C3 botulinum toxin substrate 1 (RAC1) expression in protein level, which simultaneously suppressed the epithelial-to-mesenchymal transition related protein levels and the activity of PAK1 phosphorylation, respectively. In addition, rescue experiments revealed RAC1 overexpression could reverse tumor-suppressive role of miR-142-3p. Our results showed miR-142-3p could function as a tumor suppressor via targeting RAC1/PAK1 pathway in BC, suggesting a potent therapeutic target for BC treatment. |
| |
| Keywords: | breast cancer miR-142-3p PAK1 RAC1 |
|
|
